1.Zebrafish toxicological screening could aid Leishmaniosis drug discovery
Hirla Costa Silva FUKUSHIMA ; Ricardo Lacava BAILONE ; Tatiana CORRÊA ; Helena JANKE ; Luís Kluwe De AGUIAR ; Princia Grejo SETTI ; Ricardo Carneiro BORRA
Laboratory Animal Research 2021;37(3):241-251
Background:
Recently a screen from a library of 1.8 million compounds identified in vitro a potent activity of the 2-aminobenzimidazoles series against Leishmania infantum, the etiological agent responsible by over 20.000 deaths each year. Several analogs were synthesized and in vitro tested through an optimization program, leading to a promising 2-aminobenzimidazoles derived compound (2amnbzl-d) that was progressed to in vivo mice studies. However, the not expected toxic effects prevented its progression to more advanced preclinical and clinical phases of drug development. Due to limitations of cell models in detecting whole organism complex interactions, 90% of the compounds submitted to pre-clinical tests are reproved. The use of Zebrafish embryo models could improve this rate, saving mammals, time and costs in the development of new drugs. To test this hypothesis, we compared 2amnbzl-d with two compounds with already established safety profile: carbamazepine and benznidazole, using an embryo Zebrafish platform based on acute toxicity, hepatotoxicity, neurotoxicity and cardiotoxicity assays (Pltf-AcHpNrCd).
Results:
Tests were performed blindly, and the results demonstrated the presence of lethal and teratogenic effects (CL50%: 14.8 μM; EC50%: 8.6 μM), hepatotoxic in concentrations above 7.5 μM and neurotoxic in embryos exposed to 15 μM of 2amnbzl-d. Nevertheless, benznidazole exposition showed no toxicity and only the 100 μM of carbamazepine induced a bradycardia.
Conclusions
Results using Pltf-AcHpNrCd with zebrafish reproduced that found in the toxicological tests with mammals to a portion of the costs and time of experimentation.
2.Zebrafish toxicological screening could aid Leishmaniosis drug discovery
Hirla Costa Silva FUKUSHIMA ; Ricardo Lacava BAILONE ; Tatiana CORRÊA ; Helena JANKE ; Luís Kluwe De AGUIAR ; Princia Grejo SETTI ; Ricardo Carneiro BORRA
Laboratory Animal Research 2021;37(3):241-251
Background:
Recently a screen from a library of 1.8 million compounds identified in vitro a potent activity of the 2-aminobenzimidazoles series against Leishmania infantum, the etiological agent responsible by over 20.000 deaths each year. Several analogs were synthesized and in vitro tested through an optimization program, leading to a promising 2-aminobenzimidazoles derived compound (2amnbzl-d) that was progressed to in vivo mice studies. However, the not expected toxic effects prevented its progression to more advanced preclinical and clinical phases of drug development. Due to limitations of cell models in detecting whole organism complex interactions, 90% of the compounds submitted to pre-clinical tests are reproved. The use of Zebrafish embryo models could improve this rate, saving mammals, time and costs in the development of new drugs. To test this hypothesis, we compared 2amnbzl-d with two compounds with already established safety profile: carbamazepine and benznidazole, using an embryo Zebrafish platform based on acute toxicity, hepatotoxicity, neurotoxicity and cardiotoxicity assays (Pltf-AcHpNrCd).
Results:
Tests were performed blindly, and the results demonstrated the presence of lethal and teratogenic effects (CL50%: 14.8 μM; EC50%: 8.6 μM), hepatotoxic in concentrations above 7.5 μM and neurotoxic in embryos exposed to 15 μM of 2amnbzl-d. Nevertheless, benznidazole exposition showed no toxicity and only the 100 μM of carbamazepine induced a bradycardia.
Conclusions
Results using Pltf-AcHpNrCd with zebrafish reproduced that found in the toxicological tests with mammals to a portion of the costs and time of experimentation.
3.Zebrafish as an alternative animal model in human and animal vaccination research
Ricardo Lacava BAILONE ; Hirla Costa Silva FUKUSHIMA ; Bianca Helena Ventura FERNANDES ; Luís Kluwe De AGUIAR ; Tatiana CORRÊA ; Helena JANKE ; Princia Grejo SETTI ; Roberto De OLIVEIRA ROÇA ; Ricardo Carneiro BORRA
Laboratory Animal Research 2020;36(2):98-107
Much of medical research relies on animal models to deepen knowledge of the causes of animal and human diseases, as well as to enable the development of innovative therapies. Despite rodents being the most widely used research model worldwide, in recent decades, the use of the zebrafish (Danio rerio) model has exponentially been adopted among the scientific community. This is because such a small tropical freshwater teleost fish has crucial genetic, anatomical and physiological homology with mammals. Therefore, zebrafish constitutes an excellent experimental model for behavioral, genetic and toxicological studies which unravels the mechanism of various human diseases. Furthermore, it serves well to test new therapeutic agents, such as the safety of new vaccines. The aim of this review was to provide a systematic literature review on the most recent studies carried out on the topic. It presents numerous advantages of this type of animal model in tests of efficacy and safety of both animal and human vaccines, thus highlighting gains in time and cost reduction of research and analyzes.